These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24881568)

  • 41. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
    Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
    Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
    Choi YJ; Shin D; Lee JY
    Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1.
    Yang J; Gu E; Yan T; Shen D; Feng B; Tang C
    Chem Biol Drug Des; 2019 May; 93(5):900-909. PubMed ID: 30657643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GPR40: a therapeutic target for mediating insulin secretion (review).
    Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
    Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
    Mancini AD; Poitout V
    Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
    Hamdouchi C; Maiti P; Warshawsky AM; DeBaillie AC; Otto KA; Wilbur KL; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Cr S; Lineswala JP; Neathery GL; Bouaichi C; Diseroad BA; Campbell AN; Sweetana SA; Adams LA; Cabrera O; Ma X; Yumibe NP; Montrose-Rafizadeh C; Chen Y; Miller AR
    J Med Chem; 2018 Feb; 61(3):934-945. PubMed ID: 29236497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ligands at Free Fatty Acid Receptor 1 (GPR40).
    Hara T
    Handb Exp Pharmacol; 2017; 236():1-16. PubMed ID: 27757762
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
    Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
    Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
    Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The therapeutic potential of GPR120: a patent review.
    Halder S; Kumar S; Sharma R
    Expert Opin Ther Pat; 2013 Dec; 23(12):1581-90. PubMed ID: 24094095
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.
    Carullo G; Mazzotta S; Vega-Holm M; Iglesias-Guerra F; Vega-Pérez JM; Aiello F; Brizzi A
    J Med Chem; 2021 Apr; 64(8):4312-4332. PubMed ID: 33843223
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
    Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H
    Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
    Li H; Fang Y; Guo S; Yang Z
    Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
    [No Abstract]   [Full Text] [Related]  

  • 58. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
    Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
    Negoro K; Yonetoku Y; Misawa-Mukai H; Hamaguchi W; Maruyama T; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Sep; 20(17):5235-46. PubMed ID: 22836190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.